Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News The UK MHRA has begun rolling review of Astra Zeneca’s COVID-19 vaccine candidate

The UK MHRA has begun rolling review of Astra Zeneca’s COVID-19 vaccine candidate

3rd November 2020

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has begun rolling review of Astra Zeneca’s COVID-19 vaccine candidate.

Astra Zeneca and Oxford University are both testing the AZD1222 vaccine and reached an agreement in April to produce and distribute the vaccine, granting Astra Zeneca responsibility for continuing the production and development of the vaccine as it progresses through the late stages.

The MHRA will initiate an independent review of the vaccine, using the information given by Astra Zeneca, and will then acknowledge and consider new data once it becomes available until the application is adequate to warrant the shot’s regulatory authorisation.

According to recent studies, in both younger and older adults, AZD1222 activates defensive T cell response antibodies. In addition, Astra Zeneca stressed that among the elderly, adverse responses were lower.

An Astra Zeneca spokesperson stated: “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher.”

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.